Jasper Therapeutics (JSPR) Common Equity (2019 - 2026)

Jasper Therapeutics has reported Common Equity for 8 years, with the latest figure at $1.4 million in Q2 2026.

• On a quarterly basis, Common Equity fell 93.99% year-over-year to $1.4 million in Q2 2026; TTM through Jun 2026 was $1.4 million, a 93.99% decrease from a year earlier, with the FY2025 full-year figure at $4.2 million, down 93.27% from the prior year.
• Common Equity was $1.4 million for Q2 2026 at Jasper Therapeutics, down from $4.2 million in the prior quarter.
• The five-year high for Common Equity was $125.2 million in Q1 2023, with the low at $1.4 million in Q2 2026.
• Average Common Equity over 5 years is $62.4 million, with a median of $61.7 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2026: Common Equity soared 252.87% in 2022, then slumped 93.99% in 2026.
• Over 5 years, Common Equity stood at $36.0 million in 2022, then soared by 117.96% to $78.4 million in 2023, then slipped by 21.37% to $61.7 million in 2024, then plunged by 93.27% to $4.2 million in 2025, then sank by 65.96% to $1.4 million in 2026.
• The last three Common Equity figures came in at $1.4 million (Q2 2026), $4.2 million (Q4 2025), and $11.6 million (Q3 2025), per Business Quant data.